Li Cong, Zhang Kexin, Cheng Zehua, Wang Lihong, Li Zehao, Shen Chao, Li Zhihang, Wang Zeyu, Cao Lianrui, Chen Lijiang
School of Pharmaceutical Science, Liaoning University, Shenyang 110036, China.
Liaoning Key Laboratory of New Drug Research & Development, Shenyang 110036, China.
Asian J Pharm Sci. 2024 Oct;19(5):100949. doi: 10.1016/j.ajps.2024.100949. Epub 2024 Aug 22.
Tumor metastasis is responsible for 90 % of cancer-associated deaths, and its early detection may decrease the likelihood of mortality. Studies have demonstrated that metastasis results from the interaction between "seeds" (tumor cells) and "soil" (pre-metastatic niche, PMN). As the first and most abundant immune cells to be recruited to PMN, neutrophils play a key role in the ultimate formation of metastatic foci through mechanisms such as supporting tumor cell growth, promoting angiogenesis, and shaping an immune-suppressive microenvironment. In this study, two distinct types of sialic acid (SA)-modified liposomes were prepared to target and regulate pro-metastatic neutrophils through the -selectin receptor. One of these liposomes, named ICG@SAL, was used to encapsulate indocyanine green (ICG) and was specifically designed for the early detection of cancer metastasis. The other liposome, referred to as ABE/Cur@SAL, co-loaded abemaciclib (ABE) and curcumin (Cur), with the intention of suppressing the progression of metastatic tumor. Fluorescence imaging results from the mouse spontaneous metastasis model indicated that ICG@SAL demonstrated faster targeting and stronger accumulation in the metastatic organs than unmodified ICG liposomes (ICG@CL). This suggested that ICG@SAL could detect tumor metastasis at an early stage. The therapy with co-loaded liposomes in the mouse experimental lung metastasis model indicated that ABE/Cur@SAL could inhibit regulatory T (Treg) cell proliferation, enhance effector T cell activity and reduce tumorigenic factor release, implying that ABE/Cur@SAL could inhibit tumor metastasis. Overall, our work provided a sensitive and convenient approach to early diagnosis and treatment of tumor metastasis. ICG@SAL could be employed for the early detection of tumor metastasis, while ABE/Cur@SAL could be used to inhibit the development of tumor metastasis when early metastasis was identified.
肿瘤转移导致了90%的癌症相关死亡,而其早期检测可能会降低死亡几率。研究表明,转移是由“种子”(肿瘤细胞)与“土壤”(前转移微环境,PMN)之间的相互作用引起的。作为最早被招募到PMN且数量最多的免疫细胞,中性粒细胞通过支持肿瘤细胞生长、促进血管生成以及塑造免疫抑制微环境等机制,在转移灶的最终形成中发挥关键作用。在本研究中,制备了两种不同类型的唾液酸(SA)修饰脂质体,通过P-选择素受体靶向并调节促转移中性粒细胞。其中一种脂质体名为ICG@SAL,用于包裹吲哚菁绿(ICG),专门设计用于癌症转移的早期检测。另一种脂质体称为ABE/Cur@SAL,共负载了阿贝西利(ABE)和姜黄素(Cur),旨在抑制转移性肿瘤的进展。小鼠自发转移模型的荧光成像结果表明,与未修饰的ICG脂质体(ICG@CL)相比,ICG@SAL在转移器官中的靶向速度更快、积累更强。这表明ICG@SAL能够在早期检测到肿瘤转移。在小鼠实验性肺转移模型中使用共负载脂质体进行治疗的结果表明,ABE/Cur@SAL可以抑制调节性T(Treg)细胞增殖,增强效应T细胞活性并减少致瘤因子释放,这意味着ABE/Cur@SAL可以抑制肿瘤转移。总体而言,我们的工作为肿瘤转移的早期诊断和治疗提供了一种灵敏且便捷的方法。ICG@SAL可用于肿瘤转移的早期检测,而当识别出早期转移时,ABE/Cur@SAL可用于抑制肿瘤转移的发展。